

January 13th, 2015
Symbio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer

SEC filings for Establishment of Sponsored ADR (American Depositary Receipt) Program

TOKYO, Japan, January 13th, 2015 -- Symbio Pharmaceuticals Limited (Headquarters: Tokyo, "Symbio") hereby announces that Symbio filed a Form F-6 registration statement with the U.S. Securities and Exchange Commission (SEC) for the purpose of establishing a sponsored Level I American Depositary Receipt (ADR) program in the United States. The Bank of New York Mellon is acting as the depository bank. This sponsored ADR program will not be accompanied by a listing in the U.S. or the raising of new capital through, for example, the issuance of new shares. Consequently, the total number of outstanding shares of Symbio will not increase and there will be no dilution of share value. We expect that the ADRs will start trading in the latter half of this month.

1. Purpose of establishing a sponsored ADR program

The purpose of establishing a sponsored ADR program is to enhance the convenience of U.S. investors and to develop new investors, thus expanding the overall investor base. Symbio also expects that the establishment of a sponsored ADR program will lead to greater name recognition and enhanced market reputation for Symbio in the U.S.

2. Details of the sponsored ADR program

- | | | |
|----------------------------|---|--------------------------------------|
| (1) Type of ADR program | : | Sponsored Level I program |
| (2) Trading market | : | OTC (Over-The-Counter) |
| (3) Trading effective date | : | Latter half of January, 2015(*1) |
| (4) ADR ratio | : | 1ADR = 1 share of common stock (1:1) |
| (5) CUSIP number | : | To be decided (*2) |
| (6) Ticker symbol | : | To be decided (*2) |
| (7) Depository bank | : | The Bank of New York Mellon |
| (8) Local custodian | : | Mizuho Bank, Ltd. |

*1 Trading effective date will be disclosed upon receipt of notification from the US authorities.

*2 The CUSIP and Ticker will be disclosed once determined.

[Contact]

Investor Relations

Tel: +81(0)3 5472 1125

< For Reference >

1. ADRs (American Depositary Receipts) are receipts which are issued by a depositary bank in the U.S., and represent ownership interests in the underlying securities of a non-U.S. company. When registered with the SEC, an ADR may be traded, settled and held in the same manner as shares of U.S. companies.
2. Sponsored ADRs are issued by a specified depositary bank under a depositary agreement entered into between the issuer of the underlying shares and depositary bank. The agreement defines the rights and obligations of the issuer, ADR holders and the depositary bank. Sponsored ADR programs are classified into three types; Level I, Level II, and Level III, depending on whether the program is listed, or a public offering of new or existing shares is conducted. The level of disclosure required by the SEC changes based upon these types. Level I ADR programs are unlisted programs, Level II ADR programs are listed programs (e.g., on the New York Stock Exchange), and Level III ADR programs are listed programs accompanied by the raising of new capital through an issuance of new shares.

< Note >

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.